Today: 7 February 2026
Subscribe
Browse Category

NYSE:ABT News 22 January 2026 - 3 February 2026

Abbott (ABT) stock slips on FDA warning letter over FreeStyle Libre testing; dates to watch

Abbott (ABT) stock slips on FDA warning letter over FreeStyle Libre testing; dates to watch

Abbott Laboratories shares fell 0.6% to $108.77 after the FDA issued a warning letter over quality-control lapses in its FreeStyle Libre glucose monitors. The FDA said Abbott released devices without required accuracy tests and failed to ensure specs were met by third-party manufacturers. Abbott has 15 business days to respond. Shares had dropped as much as 2.9% earlier in the session.
3 February 2026
·
Abbott (ABT) stock price steadies after Barclays trims target; Exact Sciences vote is next key date

Abbott (ABT) stock price steadies after Barclays trims target; Exact Sciences vote is next key date

Abbott Laboratories shares edged up 0.1% to $109.43 after Barclays cut its price target to $142 but kept an Overweight rating. Nutrition sales fell 8.9% last quarter, and diagnostics dropped 2.5%. Exact Sciences shareholders will vote February 20 on Abbott’s planned $23 billion takeover. The deal is expected to close in the second quarter of 2026.
2 February 2026
···
Abbott stock price today: ABT slips after Barclays cuts target as Wall Street resets expectations

Abbott stock price today: ABT slips after Barclays cuts target as Wall Street resets expectations

Abbott shares slipped 0.3% to $109.00 after Barclays cut its price target to $142 from $169, citing ongoing pressure in nutrition and diagnostics. About 6.1 million shares traded as investors awaited updates from medical meetings and the Feb. 13 dividend. The stock has struggled since missing revenue estimates and warning of slower nutrition growth in late January.
2 February 2026
·
Abbott stock price rebounds 3% after Friday rally as analysts cut targets; what’s next for ABT

Abbott stock price rebounds 3% after Friday rally as analysts cut targets; what’s next for ABT

Abbott shares closed Friday up 3.03% at $109.30, rebounding after post-earnings losses earlier in the week. Brokerages lowered price targets, citing nutrition segment challenges and a cautious outlook for early 2026. Investors are watching for updates on the Exact Sciences acquisition, expected to close in the second quarter. The S&P 500 and Dow both fell on the day.
1 February 2026
·
Abbott Laboratories stock price: ABT ends Friday up 3% — what investors watch next week

Abbott Laboratories stock price: ABT ends Friday up 3% — what investors watch next week

Abbott Laboratories shares closed up 3% at $109.30 Friday after trading between $105.72 and $109.47. CEO Robert B. Ford bought 18,800 shares on January 23 for about $2 million. The company forecast 2026 organic sales growth of 6.5%–7.5% and reaffirmed plans to acquire Exact Sciences in Q2. Abbott’s Q1 earnings and nutrition outlook remain under pressure after missing revenue estimates.
31 January 2026
·
Abbott stock rebounds as Exact Sciences vote nears after broker upgrade

Abbott stock rebounds as Exact Sciences vote nears after broker upgrade

Abbott Laboratories shares rose 2.6% to $108.89 Friday after missing revenue targets and guiding first-quarter adjusted EPS below analyst estimates. Freedom Capital Markets upgraded the stock to “buy” but cut its price target. Abbott expects to close its $23 billion Exact Sciences acquisition by Q2 2026. Exact Sciences shareholders will vote on the merger Feb. 20.
30 January 2026
···
Boston Scientific stock snaps a 4-day run — what to watch before Feb. 4 earnings

Boston Scientific stock snaps a 4-day run — what to watch before Feb. 4 earnings

Boston Scientific shares fell 1.6% to $92.33 Thursday, ending a four-day rally on heavy volume after the company completed its acquisition of Nalu Medical. The stock underperformed sector peers as investors awaited fourth-quarter results due Feb. 4 and looked for updates on recent deal activity, including the $14.5 billion Penumbra purchase.
30 January 2026
······
Abbott stock price steadies near a 52-week low as upgrade talk meets nutrition worries

Abbott stock price steadies near a 52-week low as upgrade talk meets nutrition worries

Abbott Laboratories shares rose 0.3% to $106.34 Thursday after a broker upgrade, following sharp losses from missed revenue and a cautious outlook last week. The stock touched a 52-week low of $105.27. Abbott plans to acquire Exact Sciences for $105 per share, with a shareholder vote set for Feb. 20. The company declared a $0.63 quarterly dividend, payable Feb. 13.
29 January 2026
··
Abbott stock slides after CEO’s $2 million buy hits SEC filing — what investors watch next

Abbott stock slides after CEO’s $2 million buy hits SEC filing — what investors watch next

Abbott shares fell 2.1% to $106.05 Wednesday after CEO Robert Ford bought about $2 million in stock through a family trust, according to an SEC filing. The stock has dropped 12% in five sessions following a disappointing earnings report and a price target cut by Argus. Investors are watching for updates at major medical conferences starting Jan. 29 in New Orleans.
29 January 2026
·
Abbott Laboratories stock price slides as Argus cuts target and CEO Ford discloses share buy

Abbott Laboratories stock price slides as Argus cuts target and CEO Ford discloses share buy

Abbott Laboratories shares fell about 2% to $106.12 Wednesday after Argus cut its price target to $140, following last week’s earnings warning. CEO Robert Ford bought 18,800 shares on Jan. 23 at an average $107.13, according to an SEC filing. The broader healthcare sector slipped ahead of the Federal Reserve’s rate decision. Abbott cited weak nutrition and diagnostics sales and higher costs for its recent profit miss.
28 January 2026
·
ISRG stock slips after FDA clears da Vinci 5 for heart procedures; TD Cowen starts at Buy

ISRG stock slips after FDA clears da Vinci 5 for heart procedures; TD Cowen starts at Buy

Intuitive Surgical shares fell 0.7% to $525.09 Tuesday after the FDA cleared its da Vinci 5 robot for select cardiac procedures. The S&P 500 ETF rose 0.5% and QQQ gained 0.9%. TD Cowen initiated coverage with a Buy rating and $660 target, citing potential for expanded hospital adoption. Intuitive forecasts 13–15% da Vinci procedure growth in 2026, with a 1.2% revenue hit from tariffs.
27 January 2026
····
Abbott stock price today: ABT slips as CEO buy hits SEC filing after volatile week

Abbott stock price today: ABT slips as CEO buy hits SEC filing after volatile week

Abbott Laboratories shares fell 1.2% to $107.49 by midday Tuesday after CEO Robert Ford disclosed buying 18,800 shares at an average price of $107.13. The drop followed a weak quarterly outlook and missed revenue targets, with investors watching ongoing challenges in Abbott’s nutrition segment. Health-care stocks broadly declined after a proposed near-flat Medicare Advantage payment rate for 2027.
27 January 2026
·
Abbott stock ticks higher after CEO Robert Ford buys $2 million of ABT shares

Abbott stock ticks higher after CEO Robert Ford buys $2 million of ABT shares

Abbott Laboratories shares rose about 1% Monday after CEO Robert Ford bought nearly $2 million in stock, acquiring 18,800 shares at an average $107.13 each. The stock traded at $108.49 midday. Ford now holds 253,305 shares directly and 216,203 through a trust. The purchase follows last week’s earnings report and guidance update, with Q4 adjusted earnings at $1.50 per share on $11.459 billion in sales.
26 January 2026
·
Abbott Laboratories stock faces a Monday test as ABT hovers near a 52-week low

Abbott Laboratories stock faces a Monday test as ABT hovers near a 52-week low

Abbott shares fell 10.04% Thursday, their sharpest drop since 2002, closing Friday at $107.42. Analysts cut price targets after the company reported Q4 adjusted EPS of $1.50 and warned of weak nutrition sales for “a couple quarters.” Volume spiked to 37.1 million shares. The company expects full-year 2026 adjusted EPS of $5.55 to $5.80 and plans to close its Exact Sciences acquisition in Q2.
25 January 2026
·
Abbott stock price: ABT heads into Monday after a two-day slide on nutrition worries

Abbott stock price: ABT heads into Monday after a two-day slide on nutrition worries

Abbott shares closed at $107.42, down 1.1% after a 10% plunge Thursday, as investors reacted to weak quarterly sales and a soft 2026 outlook. Nutrition sales fell 8.9% to $1.94 billion, while medical devices rose 12.3%. CEO Robert Ford cited U.S. pediatric nutrition market-share losses and price hikes for lagging volume. Abbott’s Indian unit faces scrutiny in a codeine syrup probe but is not named as a suspect.
25 January 2026
·
Abbott stock price dips again after earnings shock as analysts trim targets

Abbott stock price dips again after earnings shock as analysts trim targets

Abbott shares fell 1.1% to $107.42 in after-hours trading Friday, extending losses after the company forecast first-quarter profit below Wall Street estimates and missed revenue targets. CEO Robert Ford cited higher manufacturing costs and weaker nutrition demand. Wells Fargo cut its price target, citing headwinds in nutrition and diagnostics. Abbott reported Q4 sales up 4.4% to $11.46 billion and raised device sales 12.3%.
24 January 2026
··
Abbott stock sank 10% on earnings — what traders watch before the bell

Abbott stock sank 10% on earnings — what traders watch before the bell

Abbott shares hovered near $109 in early premarket Friday after a 10% post-earnings drop, following a fourth-quarter revenue miss driven by weakness in nutrition and diagnostics. Nutrition sales fell 8.9% to $1.94 billion, while medical-device sales rose 12.3%. The company forecast first-quarter adjusted earnings of $1.12 to $1.18 per share and expects to close its Exact Sciences acquisition in Q2.
23 January 2026
··
Abbott stock sinks 10% after outlook misses estimates — what ABT investors watch next

Abbott stock sinks 10% after outlook misses estimates — what ABT investors watch next

Abbott shares fell about 10% to $108.61 in after-hours trading Thursday after fourth-quarter revenue missed estimates and the company issued a weaker first-quarter profit forecast. Nutrition sales dropped 8.9% to $1.94 billion, and diagnostics revenue declined 2.5%. CEO Robert Ford said nutrition growth will remain “challenged” for several quarters. Abbott expects full-year adjusted earnings of $5.55 to $5.80 per share.
22 January 2026
··
1 2

Stock Market Today

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

7 February 2026
New York, Feb 7, 2026, 10:22 EST — Market closed. Eli Lilly and Company shares closed Friday up $37.34, or 3.7%, at $1,058.18. The move came as U.S. regulators sharpened their tone on “compounded” weight-loss drugs — pharmacy-made versions meant for shortages or special patient needs that have morphed into mass-market alternatives. The FDA said it would take action against telehealth firm Hims & Hers over a $49 pill it marketed as a Wegovy-like option, and Lilly said it “applauded” the agency’s action. (Reuters) Why it matters now: obesity and diabetes medicines have become the growth engine for large drugmakers,
Saudi Aramco share price set for Sunday test after Tadawul ends market-making deal

Saudi Aramco share price set for Sunday test after Tadawul ends market-making deal

7 February 2026
Saudi Exchange approved Merrill Lynch KSA’s exit as market maker for Saudi Aramco, effective Feb. 8. Aramco shares closed at 25.60 riyals Thursday, down 0.06, with 22.1 million traded. The Tadawul index fell 1.3% as Brent crude dropped to $67.93. Aramco set March official selling prices at $2.10 above Argus for North America and $0.65 above ICE Brent for Western Europe.
Meta stock ends week down about 6% as Wall Street fixates on $135 billion AI capex

Meta stock ends week down about 6% as Wall Street fixates on $135 billion AI capex

7 February 2026
Meta closed down 1.3% Friday at $661.46, capping a 6.4% weekly drop as investors questioned heavy AI spending. Amazon and Alphabet also fell after outlining major capital outlays. Meta’s Instagram suffered a brief outage this week. Legal risks persist, with trials involving Meta set for next week in Los Angeles and New Mexico.
Go toTop